Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30937055 | 0.87 | DPP4 (0.47) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL616596 | 0.84 | KMT2A (0.56) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL10274875 | 0.82 | MEN1 (0.55) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL30937160 | 0.81 | MEN1 (0.39) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL27478098 | 0.80 | KMT2A (0.53) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL18697080 | 0.80 | KMT2A (0.53) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL880655 | 0.80 | KMT2A (0.53) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL282864 | 0.80 | — | — | |
| SCHEMBL1256089 | 0.78 | MEN1 (0.61) | KMT2AMEN1SMN1; SMN2MAPTGAA | |
| SCHEMBL12125453 | 0.78 | KMT2A (0.56) | KMT2AMEN1SMN1; SMN2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | claimed |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | claimed |
| US-9238640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2016-01-19 | — | — | US | claimed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | claimed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4608816-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Monte Rosa Therapeutics AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-21 | — | — | US | disclosed |
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024092039-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | disclosed |
| EP-2090575-B1 | Processes and intermediates for the preparation of N4-phenyl-quinazoline-4-amine derivatives | ARRAY BIOPHARMA INC (US) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | disclosed |
| EP-1971601-B1 | N4-PHENYL-QUINAZOLINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA INC (US) | 2009-10-21 | — | — | EP | disclosed |
| US-7241770-B2 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-20050131004-A1 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | KMT2A 4037/4885MEN1 3826/4885SMN1; SMN2 3917/4885 |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | KMT2A 199/4885MEN1 4236/4885SMN1; SMN2 1377/4885 |
| US-20050131004-A1 | Hydronopol derivatives as agonists on human ORL1 receptors | OPRL1, ORMDL3, OGFRL1 | KMT2A 4725/4885MEN1 3895/4885SMN1; SMN2 2352/4885 |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | KMT2A 2158/4885MEN1 1492/4885SMN1; SMN2 1782/4885 |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | KMT2A 2021/4885MEN1 2754/4885SMN1; SMN2 2227/4885 |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | KMT2A 3826/4885MEN1 3913/4885SMN1; SMN2 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.